About Charnwood Campus
Charnwood Campus Science, Innovation and Technology Park
Former Astra Zeneca Charnwood Research and Development centre. Now a leading Science and Innovation Campus focusing on the biopharmaceutical sector. The first in the UK Life Sciences Opportunity Zone and a successful Enterprise Zone.
Ideally situated on the outskirts of Loughborough, in the heart of the UK, the Campus benefits from excellent transport links.
Our Vision
To become a leading next-generation life sciences cluster in the UK, driving innovation, growth and improving healthcare for all. Built on 3 sustainability pillars underpinned by adherence to best industry practices and stringent regulatory cGMP/cGLP/cGDP requirements.
Planet
Environmental considerations for the wellbeing of future generations
People
Wellbeing of the Charnwood Campus, Loughborough and wider community
Prosperity
Economic sustainability of the Campus, growth for local supply chain organisations, prosperity for the region and wider area
Experienced Team
Dr Lucille Alexander
Gosia Khrais, BSc (Hons) PGDip CQI
Johnna Bosley
Strategic Partnerships
Charnwood Campus developed a number of strategic partnerships with a range of local, regional and national governmental agencies to help realise its ambition to become a leading driver of change within the life sciences sector.
Our History
Since its inception, Charnwood Campus has safeguarded or created over 800 science jobs in the region. Charnwood Campus was formed in 2014 and has worked relentlessly to regenerate the derelict site vacated by AstraZeneca in 2011 into a sustainable science park. The Campus has created a successful formula to redevelop the site, building by building, by following suggestions included in the Transforming UK Life Science Sites - Toolkit for Action launched by Rt Hon George Freeman on Charnwood Campus in March 2016.
Charnwood Campus managed to attract and/or retain within the region a number of blue-chip organisations and several high growth SME’s have relocated to Charnwood Campus: including Almac Group’s drug development services, research, and manufacturing facility, 3M’s Health Care business operations, Kindeva Drug Delivery System’s manufacturing and R&D and Charnwood Molecular recently expanded medicinal chemistry and process research teams and related drug discovery service lines and will be relocating with recently acquired biology services company Aurelia Bioscience.
We have now 800+ scientists on-site and the Campus is helping to drive the flourishing life science cluster in the region, through the Business support programme and Talent and Skills Institute.
2024
Charnwood Campus proud of further successes of its longest partner on site
- Almac Pharma Services Announces Successful FDA Inspection at Charnwood Campus
Almac Pharma Services, a member of the privately owned Almac Group providing innovative pharmaceutical development, manufacture and commercial services to global pharmaceutical and biotech organisations, is delighted to announce the successful completion of its first US Food and Drug Administration (FDA) inspection of its commercial manufacturing facility in Charnwood, England.
The pre-approval inspection which took place over the course of five days was in relation to a solid oral dose product which the site will manufacture for a global pharmaceutical company. On completion, the inspector concluded the facility, systems and practices comply with FDA requirements with no Form 483 observations or comments reported.
Since its acquisition in 2015, Almac Pharma Services’ facility, which is set within the Charnwood Campus in Loughborough, has experienced significant growth and now employs over 250 highly skilled and experienced individuals. The site provides a wide range of oral dose development and manufacturing specialising in high potency and age-appropriate treatment options.
2024
Kindeva expands on Campus
Leading global drug-device combination product CDMO Kindeva Drug Delivery (Kindeva) and Charnwood Campus announce Kindeva’s ambitious expansion plans of their facilities at the Charnwood Campus Science Innovation and Technology Park.
This strategic move by Kindeva supports the growth of green propellant commercialization and secures a dedicated space for the company’s commercial analytical laboratory services team. The company just announced its investment in a second manufacturing line for the production of pressurized metered-dose inhaler (pMDI) products containing low GWP (Global Warming Potential) propellants at this facility.
This additional space also offers potential for further expansion to support future innovation and sustainability opportunities, including development and other supporting capabilities in one location.
2024
Solventum UK Headquarters at Charnwood Campus
Charnwood Campus welcomed the news of Solventum, the healthcare spin-off from 3M, confirming its intention to establish its UK headquarters at Charnwood Campus Science Innovation and Technology Park.
Solventum is a proven global leader in large, diverse and growing markets and is well positioned for success with a diverse portfolio of strong, trusted, reputable brands and deep innovation capabilities and an excellent addition to Charnwood life sciences cluster. Solventum solutions span across four business segments – Medical Surgical, Dental Solutions, Health Information Systems and Purification and Filtration.
2024
Health Minister opens Leicestershire Innovation Festival, Life Sciences Day
Andrew Stephenson CBE MP visited Charnwood Campus to join more than 100 delegates considering innovation as a potential solution to health disparities and inequalities. The minister endorsed the event and highlighted that programmes like this are a fantastic opportunity to bring together government, industry and academia to collaborate, discuss and drive forward innovation.
Attendees included senior representatives from the NHS, as well as clinicians, researchers, and life science business leaders who engaged in a discussion around the impact on the physical and mental wellbeing, and life chances, of individuals in most-impacted groups.
Day-long event allowed the opportunity to recognised the work and growth of the life science organisations clustered around Charnwood Campus Science, Innovation and Technology Park in Loughborough.
Mr Stephenson went on to tour contract development and manufacturing organisation Kindeva Drug Delivery, which recently invested £30 million into its inhaler sustainability programme in Loughborough.
2023
£4.6m Investment will bring 222 jobs to world class lab space
Charnwood Campus announced investment into B28East. The investment will create more than 200 jobs and over 60,000sqft of highly-specialised biochemistry lab space.
The project will enable a number of research organisations to expand into the LLEP area and further strengthen Leicestershire’s emerging CRO cluster.
The investment will be partially provided through the Charnwood Campus Enterprise Zone retained rates reinvestment scheme managed by the Leicester and Leicestershire Enterprise Partnership (LLEP) and Charnwood Borough Council.
2022
Charnwood Discovery
Leading UK pre-clinical discovery CRO servicing the global pharmaceutical and biotechnology market, Charnwood Discovery, has joined Charnwood Campus and expanded its operations in a deal expected to support the growth of its contract research services. Charnwood Discovery’s ambitious growth plans now see the company becoming the sole occupier of a substantial three-storey, state-of-the-art laboratory facility at Charnwood Campus.
2021
LSTSI
Launched in October 2021 and endorsed by Rt. Hon George Freeman Charnwood Campus Life Sciences Talent and Skills Institute is an exemplar platform where industry and academia work together to solve short and long term skills challenges by creating a clear path from study to the workplace, circular development and upskilling employees.
2021
Kindeva
Global contract development and manufacturing organisation (CDMO) Kindeva Drug Delivery has expanded its operations at Charnwood Campus, in a deal to support Kindeva’s continued growth in the UK. The US-headquartered company has taken over a state-of-the-art research and development facility at Charnwood Campus, and a further 20,000 square feet of office space at the site.
2020
Lighthouse Lab
COVID-19 testing ‘Lighthouse Lab’ opens at Charnwood Campus. A new ‘Lighthouse Lab’ facility will be established in Leicestershire to increase the UK’s COVID-19 testing capacity, in an investment creating 400 jobs. The UK Department of Health and Social Care’s Lighthouse Lab at Charnwood Campus in Loughborough is a partnership with global diagnostics company PerkinElmer.
2019
3M
3M Drug Delivery Systems Relocates U.K. R&D to New, State-Of-The-Art Facility. 3M Drug Delivery Systems (DDS) U.K. organization is bringing its teams under one roof, with 120 research and development employees moving to the DDS R&D Inhalation Centre of Excellence, Building 39.
2018
3M
The science-based technology company 3M has begun the next era in its long relationship with Loughborough after the official opening of new offices on Charnwood Campus. Some 170 employees have relocated to Building 47 on the science, technology and enterprise park from 3M’s previous site at Morley Street, where it had been based since the early 1950s. Their new 3,400m2 home has office space arranged over three floors within half a mile of the company’s Derby Road manufacturing and distribution site.
2017
LSOZ
Charnwood Campus is endorsed as the first UK Life Science Opportunity Zone (LSOZ) and therefore the site benefits from engagement with government ministers and officials from the Department for International Trade and the Office for Life Science as part of the Life Sciences Industrial Strategy.
2016
Ministerial Visit
Life Science’s Minister George Freeman MP visited Charnwood Campus in Loughborough to meet the team responsible for the transformation of the world-class pharmaceutical site, and to discuss its potential role in strengthening the local economy. His visit coincided with the publication of a new report, ‘Transforming Life Sciences Sites – a toolkit for action’ by a group of senior stakeholders from across the UK¹.
2016
Almac Group
Almac Group expands its UK operations to Loughborough. Almac Group provides integrated drug development services, research and manufacturing to about 600 clients worldwide within diagnostics, clinical services, clinical technologies and pharmaceutical sectors.
2015
First tenants on the campus
ARM
ARM specializes in developing cutting-edge, next-generation camera and display subsystems, bringing deep knowledge of human visual processing to create the best possible image quality and new user experiences.
2014
Collaborations
Close cooperation with Charnwood Council, Leicester City Council, Medilink East Midlands, LLEP, Business Innovation & Skills, and Office for Life Sciences resulted in firming up Charnwood Campus Investment and Implementation Strategy.
2000
Astrazeneca
Fisons bought by Astra. Merged with Zeneca of Sweden to form Astrazeneca.
1990
Expansion
Expansion with the building of the Biology and Chemistry facilities.
1980
Expansion
Modernisation and expansion programme with the building of the pharmacology building.
1960
TILADE
Construction of new research and manufacturing buildings was completed at Bakewell Road. The discovery and development of a second inhaled compound was subsequently marketed as TILADE. Other projects were started with significant compounds being discovered and also the discovery of DOPACARD
1950
INTAL
The significant discovery of INTAL, a fundamentally new approach to asthma therapy, was well under way during the 1950s and was marketed in 1968.
1930
Fisons
Fisons (which dated back to the 1700s). Fisons bought a part share in the then Loughborough-based company Genatosan, manufacturers of Sanatogen nerve tonic.